In a randomized controlled trial of six cycles of docetaxel 3 weeks apart in addition to ADT, median survival among men with castrate sensitive, metastatic disease randomized to receive docetaxel was 14 months longer than men receiving ADT alone (57.6 vs 44.0 months).32 Other predictors of variability in an individual's response to ADT include timing of treatment (immediate vs delayed), use of bisphosphonates, pretreatment PSA levels, testosterone nadir, and time to PSA nadir after treatment. The gene discussed is KLK3; the disease is metastatic neoplasm.